Iron dextran |
Catalog No.GC60940
One-Click Copy Product Info
|
Iron dextran is an injectable complex comprising ferric hydroxide and a low-molecular-weight fraction of dextran. Iron dextran is a type of intravenous iron agent specifically used for the treatment of iron deficiency anemia.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9004-66-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Iron dextran is an injectable complex comprising ferric hydroxide and a low-molecular-weight fraction of dextran. Iron dextran is a type of intravenous iron agent specifically used for the treatment of iron deficiency anemia[1].
In vitro, Iron dextran(1.9–4000μg/ml; 24h) exhibited certain cytotoxicity to HepG2 cells, with a half - inhibitory concentration (IC50) of 1178μg/ml. When used in combination with TQ (thymoquinone), TQ at a specific dose would enhance its toxicity[2].
In vivo, Iron dextran (200mg/kg/every other day; 1,2,3 or 4 weeks; i.p.) induces iron overload and CTSB/CTSD up-regulation in the liver and spleen of mice[3]. Iron dextran (0, 1.1, 3.3 and 9.9mg/(100g·bw·d); 4 weeks; i.g.) played an important role in improving iron deficiency anemia, promoting vitamin D metabolism and activation, regulating iron metabolism balance, and promoting growth and development in rats[4].
References:
[1] Failla S, Nicolas S, Parmar M. Iron Dextran. 2024 Feb 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Failla S, Nicolas S, Parmar M. Iron Dextran. 2024 Feb 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491679.
[2] Ghasemi F, Ghaffari F, Omidifar N, Taheri Azandaryani M, Nili-Ahmadabadi A. Hepatic Response to the Interaction Between Thymoquinone and Iron-Dextran: an In Vitro and In Vivo Study. Biol Trace Elem Res. 2023 Mar;201(3):1358-1367.
[3] Liang M, Chen L, He Q, Mi X, Qu L, Xie J, Song N. Intraperitoneal injection of iron dextran induces peripheral iron overload and mild neurodegeneration in the nigrostriatal system in C57BL/6 mice. Life Sci. 2023 May 1;320:121508.
[4] Qiu F, Li R, Gu S, Zhao Y, Yang L. The effect of iron dextran on vitamin D3 metabolism in SD rats. Nutr Metab (Lond). 2022 Jul 16;19(1):47.
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | The HepG2 cell line was cultured in 25cm² flasks containing HG-DMEM medium supplemented with 1% penicillin-streptomycin and 10% fetal bovine serum. The cells were maintained in a humidified atmosphere of 5% CO₂ at 37°C. For cytotoxicity experiments, HepG2 cells were seeded at a density of 10,000 viable cells per well in sterile 96-well plates and incubated overnight at 37°C and 5% CO₂. In the first step, the cells were treated with different concentrations of TQ (0.5-300×10³nM) and Iron dextran (1.9-4000µg/ml) for 24 hours, and the cell viability was determined using the MTT method separately. In the next step, HepG2 cells were pretreated with safe doses of TQ (1.8-15×10³nM) before being exposed to various concentrations of Iron dextran. After 24 hours, 0.5mg/ml of MTT reagent was added to each well and incubated for 4 hours. Finally, 100µl of dimethyl sulfoxide (DMSO) was added to each well to dissolve the formazan crystals, and the changes in absorbance were measured at 570nm using a microplate reader. |
Reaction Conditions | 1.9-4000µg/ml; 24h |
Applications | Iron dextran exhibited certain cytotoxicity to HepG2 cells, with a half - inhibitory concentration (IC50) of 1178μg/ml. When used in combination with TQ (thymoquinone), TQ at a specific dose would enhance its toxicity. |
| Animal experiment [2]: | |
Animal models | 8-week-old male C57BL/6 |
Preparation Method | Eight-week-old mice were housed in a near pathogen-free environment (temperature 20°C ± 2°C, humidity 50%–60%, 12h light/dark cycle), with four animals per polypropylene cage and food and water provided ad libitum. Mice were intraperitoneally injected with 200mg/kg Iron dextran every other day for 1, 2, 3, or 4 weeks. Control mice were injected with the same amount of saline. |
Dosage form | 200mg/kg; 1, 2, 3, or 4 weeks; i.p. |
Applications | Iron dextran induces iron overload and CTSB/CTSD up-regulation in the liver and spleen of mice. |
References: | |
| Cas No. | 9004-66-4 | SDF | |
| Canonical SMILES | [Iron dextran] | ||
| Formula | M.Wt | ||
| Solubility | Iron, ~100 mg/mL in water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solution in water
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)